A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 161 (final count)
- Started
- Aug 17, 2020
- Main results expected
- Oct 29, 2024
- Fully finished
- Oct 29, 2024
- Results posted
- Dec 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to approximately 24 months
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Up to Cycle 1 (each cycle was of 21 days)
Phase 1: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to approximately 24 months
Phase 1: Number of Participants With One or More Serious Adverse Events (SAEs)
Measured over: Up to approximately 24 months
Phase 1: Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation
Measured over: Up to approximately 24 months
Phase 1: Number of Participants With Clinically Significant Laboratory Values
Measured over: Up to approximately 24 months
Phase 2: Overall Response Rate (ORR) as Assessed by the Investigator According to RECIST, Version 1.1
Measured over: Up to approximately 25 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04381650 · record last updated 2025-12-10 · checked 2026-11-09 15:47 UTC